AEON Biopharma(AEON) - 2024 Q3 - Quarterly Results

Exhibit 99.1 PRESS RELEASE AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update – Held biosimilar advisory meeting with FDA in Q3 2024, and aligned on next steps for a 351(k) regulatory pathway to approval for ABP-450 (prabotulinumtoxinA) as a biosimilar utilizing BOTOX® (onabotulinumtoxinA) as the reference product – – Plan to initiate comparative analytical studies anticipated in Q4 2024 subject to available resources – – 351(k) regulatory pathway offers potential to b ...